key: cord-1044586-qzime3u2 authors: Frohman, Elliot M.; Cruz, Roberto Alejandro; Longmuir, Reid; Steinman, Lawrence; Zamvil, Scott S.; Villemarette-Pittman, Nicole R.; Frohman, Teresa C.; Parsons, Matthew S. title: Part II. High-dose methotrexate with leucovorin rescue for severe COVID-19: An immune stabilization strategy for SARS-CoV-2 induced ‘PANIC’ attack() date: 2020-05-21 journal: J Neurol Sci DOI: 10.1016/j.jns.2020.116935 sha: 25ba212f9723594b8351c198b7080f9e3e71f075 doc_id: 1044586 cord_uid: qzime3u2 Here, in Part II of a duology on the characterization and potential treatment for COVID-19, we characterize the application of an innovative treatment regimen for the prevention of the transition from mild to severe COVID-19, as well as detail an intensive immunotherapy intervention hypothesis. We propose as a putative randomized controlled trial that high-dose methotrexate with leucovorin (HDMTX-LR) rescue can abolish ‘PANIC’, thereby ‘left-shifting’ severe COVID-19 patients to the group majority of those infected with the SARS-CoV-2 virus, who are designated as having mild, even asymptomatic, disease. HDMTX-LR is endowed with broadly pleiotropic properties and is a repurposed, generic, inexpensive, and widely available agent which can be administered early in the course of severe COVID-19 thus rescuing the critical and irreplaceable gas-exchange alveoli. Further, we describe a preventative treatment intervention regimen for those designated as having mild to moderate COVID-19 disease, but who exhibit features which herald the transition to the severe variant of this novel Coronavirus. Both of our proposed hypothesis-driven questions should be urgently subjected to rigorous assessment in the context of randomized controlled trials, in order to confirm or refute the contention that the approaches characterized herein, are in fact capable of exerting mitigating, if not abolishing, effects upon the SARS-CoV-2 triggering of the ‘PANIC Attack’. Confirmation of our immunotherapy hypothesis would have far-reaching ramifications for the current pandemic, along with yielding invaluable lessons from which we can more effectively prepare for the next challenge to global health. transition to the severe variant of this novel Coronavirus. Both of our proposed hypothesisdriven questions should be urgently subjected to rigorous assessment in the context of randomized controlled trials, in order to confirm or refute the contention that the approaches characterized herein, are in fact capable of exerting mitigating, if not abolishing, effects upon the SARS-CoV-2 triggering of the 'PANIC Attack'. Confirmation of our immunotherapy hypothesis would have far-reaching ramifications for the current pandemic, along with yielding invaluable lessons from which we can more effectively prepare for the next challenge to global health. We submit that the best chance to rescue those afflicted with the severe variant of COVID-19 depends upon the decision to intervene with a corresponding assemblage of diverse immune modulatory agents, each directed toward a mechanistically distinctive component of the activated inflammatory network. Such a diverse combination of agents would require a synchrony of action in order to arrest the 'irrationally exuberant', poorly coordinated, and regulatory-deficient immune network in severe COVID-19 patients. The prolific activation, and expansive constellation of coincidentally activated inflammatory cascades, confers potentially destructive consequences upon host tissue compartments which harbor the SARS-CoV-2 agent (i.e. bystander damage). In contrast to the application of a multi-component treatment strategy, the identification of a single agent endowed with pleiotropic mechanistic properties, and capable of reconstituting the normally coordinated immune-regulatory response characteristics to SARS-CoV-2, would represent a potential advance in our struggle to transition severely affected COVID-19 patients into the 'mild' phenotypic variant of this Coronavirus-mediated disorder. give pause to consider the prospect of acute and directed interventions, which may potentially serve to mitigate symptoms and reduce the risk of advancing to a more severe clinical state with an associated worsening prognosis. Such issues can involve recalcitrant cough, poor mucus clearance, perception of a diminished negative inspiratory force of breathing, and risk of secondary upper respiratory tract infection. Treating a recalcitrant cough may be as simple as offering dextromethorphan, but the addition of quinidine can reduce the former's metabolism and thereby prolong its action, A dose of 20mg/10mg respectively is the composition of Nuedexta which is FDA-approved for pseudobulbar affect, but can be of great utility in the circumstances of recalcitrant cough. An expectorant, such as guaifenesin, may aid in mucus clearance, whereas a bronchodilator may improve perception of a diminished negative inspiratory force of breathing. Smooth muscle relaxation at the terminal bronchioles and activation of the beta-2 adrenergic receptor on lung mononuclear cells may skew the immune milieu from a TH1 to a TH2 antiinflammatory phenotype. The intracellular biomarker, secondary to transmembrane signaling at the beta-2 adrenergic receptor, is an escalation of cAMP an intracellular biomarker for this effect [1] [2] [3] [4] . A bronchodilator in conjunction with inhalational steroids will likely reduce peripheral airway inflammation. Antibiotics, such as azithromycin, will mitigate risk of secondary upper respiratory tract infection. Interventions that help detect worsening, such as home finger pulse oximetry, may be useful. This multi-faceted interventional approach may prevent the transformation of the mild phenotype into the severe disease course and its correspondingly worse prognosis [Vignette from patients dichotomized to the mildly affected cohort, and administered to more severely affected patients, can exhibit impressive remission-exacting effects [5] [6] [7] . This salient observation, in conjunction with inadequate evidence to confirm the relevance of SARS-CoV-2 antibodies, makes it is entirely feasible to assume that one, or even a variety of plasmaderived soluble factors from recovered COVID-19 patients, may serve to promote recovery in severely affected patients. Those dichotomized into the 'severe COVID-19' subgroup, because of their 'PANIC Attack' response phenotype, fail to organize the coordinated neutralization of the SARS -CoV-2 virus, in contradistinction to mildly to moderately affected patients who do in fact eventually orchestrate effective clearance of the COVID-19 pathoetiologic agent. Alternately, the severely affected cohort of patients will exhibit evidence of the coincident activation of both the innate and adaptive limbs of the inflammatory response network; which is in keeping with our definition of the 'prolific activation of a network-immune-inflammatory crisis' (i.e. PANIC), and provides an attractive explanation for why the most severely affected COVID-19 patients harbor stereotyped patterns of irreversible tissue destruction, including but not limited to, the obliteration of the life-sustaining process of gas exchange within the terminals of the bronchopulmonary tree. The anti-IL-6 monoclonal antibody, tocilizumab, has been shown to provide a mitigating effect upon the CRS, in addition to reducing fevers, CRP levels, and improving the chest CT demonstrated lung abnormalities (e.g. the ground glass opacifications) in COVID -19 positive patients [8, 9] . Tocilizumab is a humanized anti-interleukin-6-receptor (IL-6R) monoclonal antibody (mAb) that inhibits interleukin-6 (IL-6) signaling. However, morbidity and mortality are not markedly altered by the administration of this single-targeted immunotherapeutic intervention. The observation of the CRS appears to be, at least in part, secondary to the accelerated viral replication characteristics within the peripheral lung alveolar network, ultimately culminating in the massive release of newly assembled virions during cellular apoptosis, a process which also results in the release of pro-inflammatory mediators. Apoptosis resulting in the exaggerated and paroxysmal release of inflammatory effector elements is now referred to as pyroptosis [11] . In fact, pyroptosis is the process most likely responsible for the pathobiologic underpinnings of the so-called 'cytokine storm' (representing an important albeit one mechanism among a constellation of pathobiological underpinnings, which collectively represent the new rubric, which we have defined as PANIC) which involves the rapid release of a broad repertoire of cytokine and chemokine effector elements including TNF-α, IFN-γ, IL-1β, IL-6, IL-12, IL-18, IL-33, TGFβ; CCL2, CCL3, CCL5, CXCL8, CXCL19, and CXCL10 [11] . In conjunction with the CRS, the SARS-CoV-2 virus is further able to provoke what we believe to represent a redistribution of immune effector cells into the lungs, with the consequent intensification of tissue damage secondary to such cells releasing their corresponding effector elements, free radicals and reactive oxygen species, such as super oxide (O -). The viral spike glycoprotein which decorates the outside surface of SARS-CoV-2, and serves as the ligand for ACE-2 receptor, also happens to represent a strongly immunogenic portion of the viral architecture [12] . During the process of viral binding to the alveolar ACE-2 receptor, in addition to utlizing the endosomal pathway for its tropism, the SARS-CoV-2 can integrate its membranous envelope with that of the alveoli epithelium, leading to multinucleated cell formation [ Figure 3 in Part I]. In virology, such cross-species fusion elements are designated as syncytia. The specific SARS-CoV-2 agent fuses its membrane in such a way that the resulting syncytium includes the strategic externalization of the spike protein, which can then interact with anti-spike IgG (possibly also IgM) antibodies. The result is the establishment of antigenantibody complexes capable of complement fixation, and ultimately complement-dependent cellular (alveoli epithelium representing the 'kill-target' in this case) cytotoxicity [see 'H' in A primary aim of this 2-part series has been to advance and substantiate the hypothesis that the pathobiological underpinnings of severely affected COVID-19 patients is principally related to the 'PANIC' Attack we have described throughout. Specifically that such patients mount exaggerated and injurious inflammatory cascades spanning the broad dynamic range of the effector mechanisms which endow the human immune network. The unintended consequences of this process include bystander tissue injury, particularly destruction of the most distal microanatomy of the bronchopulmonary tree, given the proclivity of the SARS -CoV-2 spike glycoprotein binding to the robust expression of ACE2 receptors on the alveolar epithelium. The pleiotropic mechanisms of tissue injury involved in severely affected COVID-19 patients mean that targeting a single regulatory cytokine (e.g. IL-1 or IL-6) is highly unlikely to adequately uncouple the confluence of convergent inflammatory cascades that appear to rapidly descend upon the bronchopulmonary tree, ultimately resulting in an irreversible and step-wise decrement of the alveolar gas-exchange apparatus. When a critical corpus of lung alveoli are lost, there is an accelerated failure to adequately load oxygen sufficient to deliver the substrate required for aerobic respiration. Virtually every system of the body requires aerobic respiration in order to maintain the constant bioenergetic balance between supply and demand of energy substrate for purposes of homeostasis. The respiration demands of a multiorgan system that operates across a dynamic range of metabolic circumstances with corresponding and rapidly fluctuating energy production and delivery characteristics must be met or catastrophe ensues. Our hypothesis is that in the ~20% of SARS-CoV-2 infected patients with severe COVID-19, activation of innate and adaptive immune cascades working in synchrony inflict a 'PANIC Attack' upon the terminal lung fields. The outcome inevitably involves a hyperacute, and potentially diffuse, malfunction of the incredibly delicate functional interface between the alveolar epithelium and the single cell thick endothelial tubes, which comprise the capillaries derived from the pulmonary arteries and those which subsequently become the oxygen-rich blood vessels which enter into the pulmonary veins. We can ill afford to permit such a PANIC Attack to proceed without interruption, knowing that a catastrophic loss of alveoli will ultimately J o u r n a l P r e -p r o o f Journal Pre-proof bring the severe COVID-19 patient to the pathophysiologic threshold beyond which the lungs will fail to both transfer and load oxygen onto red cell hemoglobin, and to expel carbon dioxide. We propose a potentially innovative hypothesis, whereby the application of an available, intensive, and highly pleiotropic immunotherapy, is characterized by commensurately synchronous and diametrically opposed actions serving to attenuate the specific sequence of SARS-CoV-2 triggered PANIC Attack mechanisms. We have employed this strategy for a number of fulminant and treatment recalcitrant inflammatory disorders of the CNS, that upon careful analaysis, suggests that the immune phenomenonlogy, whether triggered by a foreign microbe, an adjuvant-enriched vaccine, or the 'ignition' of a monumentally severe exacerbation of autoimmunity, all appear to exhibit common pathobiological mechanisms reminiscent of our definition for the SARS-CoV-2 triggered PANIC Attack. Our proposed strategy may serve to abort the uncoordinated and poorly regulated host immune activities, which appear to be fundamentally germane to the development of severe COVID-19, and which determine its prognostic disposition if the PANIC Attack proceeds with impunity. Further, we present a vignette [Vignette 1] of a patient with initially mild COVID -19 disease, who began to exhibit what we suspected were transformational clinical features at high risk for advancing to severe COVID-19, and underscore our multi-modal intervention strategy for 'left-shifting' away from the transition to severe COVID-19. We follow with a second vignette which underscores the utility of the application of the HDMTX-LR protocol (the details of which are provided as a supplement at the end of the paper, but also detailed in our flow diagram on dichotomizing mild/moderate COVID -19 from the severe variant, and their respective proposed treatment interventions [Flow Diagram]. We suggest that high-dose methotrexate with leucovorin rescue (HDMTX-LR), an antiinflammatory and chemotherapeutic agent, is endowed with impressive mechanistically pleiotropic properties [ Table 1 Adenosine promotes its action through interaction with its receptor A2a and ADORA3, where transmembrane signaling activities result in the reduction of production and release of pro-inflammatory cytokines such as IL-1β, TNFα, IL-6, and reduction in the production of matrix metalloproteinases (MMPs) (the transcription of each requires NF-κB). An additional action of MTX is the inhibition of NFκB as well as the escalation in their corresponding tissue inhibitors (TIMPs). Methotrexate inhibits catabolism of adenosine and AMP, while increasing release of both ATP and ADP from inflammatory cells; an effect which modulates the bioenergetic activity, such that inflammatory cells are diminished in their ability to foment unchecked proinflammatory effector mechanisms [16, 17] . A significant pathway responsible for the transduction of multiple pro-inflammatory cytokines is the JAK/STAT signaling platform, which is potently suppressed by mechanisms independent of the folate inhibition effects of MTX, as such effects are not reversed by administration of folinic acid [ Figure 1B ]. involved in the heightened expression of pro apoptotic genes which increase the propensity to apoptosis [ Figure 1 ]. The high-mobility group box chromosomal protein 1 (HMGB1) is elaborated by activation or injured immune cells, including monocytes, macrophages, and dendritic cells, and mediates inflammation [ Figure 1C ]. One such example is called 'alarmin', which promotes acute inflammation followed by tissue repair [22] [23] [24] . The effects of HMGB1 is through its counterreceptor, a receptor for advanced glycan end products (RAGE), and is associated with cell maturation and migration to the site of injury, whereby chronic inflammation is perpetuated [25, 26] . Methotrexate can inhibit HMGB1 by directly binding to RAGE or indirectly by inhibition of cytokine production of TNFα, IL -1, IL-6, IL-8. The proposed HDMTX-LR protocol has been the focus of prior investigation, the details of which have been published [27] [ Table and The addition of benfotiamine has been shown to reduce MTX mediated liver toxicity in those utilizing low dose weekly chronic dosing of the medication, and the addition of this agent to the high dose punctuated administration of MTX may also confer some tangible benefits, albeit a subject for further investigation. Further, adequate levels of vitamin D (to achieve 60-100ng/ml) are known to exert immunomodulatory effects [28] . The principal thrust of this paper is to emphasize that the SARS-CoV The primary goal of this communication is to help our front line workers recognize that despite the 'prolific activation of a network-mediated inflammatory crisis', or PANIC Attack, we do in fact have compositional immunotherapies, that when combined together (as in the era of discovery of highly active anti-retroviral therapy (HAART)), may serve to abort or at least mitigate, suffering while promoting an improved prognosis. Alternately, we herein hypothesize that a single agent endowed with a plethora of diverse and site selective targeting capabilities, each of which is sufficiently robust so as to uncouple the SARS-Co-V-2 induced PANIC Attack, may be used to lead the counter-attack. It is precisely for this reason that the WHO has long considered MTX as a 'necessary' medicine. About 20% of COVID-19 patients will ultimately advance to severe disease, with assimilation of the corresponding risk escalation of both morbidity and mortality. Most COVID -J o u r n a l P r e -p r o o f Journal Pre-proof remediable, and potentially even mitigated with respect to 'left-shifting' the patient and their course, further away from those thresholds beyond which survival becomes increasingly more remote. To illustrate, we have prepared two scenarios as 'call out boxes' which contain an abbreviated vignette, followed by our specific plans of intervention [Box 1 and 2]. The goals for each scenario are to mitigate suffering, promote reconstitution of network immune coordinate regulation sufficient to prevent PANIC, but also to recognize and urgently treat PANIC when the features that define it are recognized by our front-line workers. As a synopsis, the mildly affected COVID-19 patient is offered site-selected delivery of inhalational steroids followed by L-albuterol (R form of this agent, making it relatively lung selective). This promotes bronchial smooth muscle relaxation, as well as activates the beta-2 adrenergic receptor on immune cells, thereby rendering them diminished in their inflammatory activity via activation and escalation of intracellular cyclic AMP (essentially biasing immune cells from a TH1 to TH2 anti-inflammatory phenotype). Further, low-dose weekly MTX (7.5 to 25mg taken po weekly along with 2mg of folate daily) could be utilized in those patients with mild to moderate COVID-19, but who persist or exhibit what appears to represent a more protracted and slowly advancing clinical deterioration. When compared to our HDMTX-LR intervention, low dose weekly oral MTX is not as prolific, nor as rapidly acting to exact remission. It can, nevertheless, exert a constellation of attenuating influences in response to the SARS-CoV-2 triggering of the broad expanse of the host immune networks. Pulmonary toilet (now referred to as pulmonary hygiene) can loosen and expectorate mucus in the distal bronchopulmonary tree, which is facilitated by the performance of postural percussion of the back and sides of the thoracic cage. For chronic cough, dextromethorphan + quinidinemay be prescribed, the latter reducing the metabolism of dextromethorphan while also providing a derivative of quinine from the cinchona tree. Quinine, like chloroquine and hydroxychloroquine, has demonstrated interrupted viral synthesis in vitro, as well as the release of cytokines. Vitamin D3 taken daily, and at a dose commensurate to achiving a blood level of 60-100ng/ml, can promote immune regulatory networks, and improve energy (reduce fatigue) [29] . A decision was made to discontinue the dimethyl fumarate, and to instead begin treatment with interferon beta 1a, taken SQ every two weeks (Plegridy). Further, given that the patient exhibited breakthrough on interferon in the past, it was also decided to treat concomitantly with teriflunomide; starting at 7mg po daily for two weeks; then escalating to 14mg daily thereafter. A randomized controlled doublemasked trial of albuterol add-on therapy in patients with multiple sclerosis Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol) Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis Beta2-adrenergic agonist use and the risk of multiple sclerosis: a total population-based case-control study Operational protocol for donation of anti-COVID-19 convalescent plasma in Italy. Vox Sang Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang Mechanisms and management of chimeric antigen receptor T-cell therapy related toxicities Current concepts in the diagnosis and management of cytokine release syndrome Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome:reanalysis of a prior phase iii trial Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARSCoV infection Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma Risk of liver disease in methotrexate treated patients Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-50 -nucleotidase: Findings in a study of ecto-50 -nucleotidase gene-deficient mice Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species Endothelial dihydrofolate reductase: Critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase Proc. Natl. Acad. Sci Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis HMGB1: Endogenous Danger Signaling High-mobility group box 1 (HMGB1) as a master regulator of innate immunity Release of chromatin protein HMGB1 by necrotic cells triggers inflammation Advanced glycation end product receptor-mediated cellular dysfunction High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes Protective effects of benfotiamine on irisin activity in methotrexateinduced liver injury in rats COVID-19 and vitamin D-Is there a link and an opportunity for intervention? Blood pressure monitoring and correlate with headache.